Original research: Primary and additional treatment preference in aggressive retinopathy of prematurity and type 1 retinopathy of prematurity

BMJ Open Ophthalmology

article

Ji Hye Jang¹  Yong Koo Kang²  Han Sang Park²  Kiyoung Kim³  Sung Soo Kim⁴  Jae Yong Han⁴  Hyun Wong Kim⁵  Jong Wook Bang⁵  Jae Shin Song⁶  Sang Jun Park⁶  Se Joon Woo⁶  Kwang Sic Joo⁶  Woong-Sun Yoo⁷  Inyoung Chung⁷  Yong-Wun Cho⁷  Jong Hyun Lee⁸  Hun Jin Choi⁸  Yoo-Ri Chung⁹ 

[1] Department of Ophthalmology, Dongsan Medical Center , Keimyung University School of Medicine;Department of Ophthalmology , Kyungpook National University School of Medicine;Department of Ophthalmology , Kyung Hee University School of Medicine;The Institute of Vision Research, Department of Ophthalmology, Severance Hospital , Yonsei University College of Medicine;Department of Ophthalmology, Haeundae Paik Hospital , Inje University College of Medicine;Department of Ophthalmology, Seoul National University Bundang Hospital , Seoul National University College of Medicine;Department of Ophthalmology , Gyeongsang National University School of Medicine;Department of Ophthalmology, Ilsan Paik Hospital , Inje University College of Medicine;Department of Ophthalmology , Ajou University School of Medicine

关键词: Retina;    Treatment Lasers;    Treatment Medical;   

DOI  :  10.1136/bmjophth-2022-001166

学科分类：工业工程学

来源: BMJ Publishing Group

【 摘 要 】

Objective This study aimed to evaluate the preference for antivascular endothelial growth factor (anti-VEGF) versus laser ablation therapy as primary and additional treatment in aggressive retinopathy of prematurity (ROP) and type 1 ROP.Methods This multicentre retrospective study was conducted at nine medical centres across South Korea. A total of 94 preterm infants with ROP who underwent primary treatment between January 2020 and December 2021 were enrolled. All eyes were classified as having type 1 ROP or aggressive ROP. Data on the zone, primary treatment chosen, injection dose, presence of reactivation and additional treatment were collected and analysed.Results Seventy infants (131 eyes) with type 1 ROP and 24 infants (45 eyes) with aggressive ROP were included. Anti-VEGF injection was selected as the primary treatment in 74.05% of the infants with type 1 ROP and 88.89% with aggressive ROP. Anti-VEGF injection was selected as the ROP was located in zone I or posterior zone II, and laser ablation was selected when it was located in zone II. The anti-VEGF injection doses varied and tended to be higher in the aggressive ROP group. Infants with aggressive ROP were 2.08 times more likely to require additional treatment than those with type 1 ROP. When ROP reactivation occurred, laser therapy was preferred as an additional treatment.Conclusion In Korea, the preference for anti-VEGF therapy or laser therapy differed according to ROP subtype, zone and primary or secondary treatment. These findings suggest that ROP treatment are considered according to ROP subtype, location and reactivation.

【 授权许可】

CC BY-NC|CC BY|CC BY-NC-ND